JP2017538675A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538675A5 JP2017538675A5 JP2017523903A JP2017523903A JP2017538675A5 JP 2017538675 A5 JP2017538675 A5 JP 2017538675A5 JP 2017523903 A JP2017523903 A JP 2017523903A JP 2017523903 A JP2017523903 A JP 2017523903A JP 2017538675 A5 JP2017538675 A5 JP 2017538675A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- substituted
- inhibitor
- unsubstituted
- rnase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 45
- 239000003112 inhibitor Substances 0.000 claims description 32
- 102000004167 Ribonuclease P Human genes 0.000 claims description 18
- 108090000621 Ribonuclease P Proteins 0.000 claims description 18
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 102000052866 Amino Acyl-tRNA Synthetases Human genes 0.000 claims description 12
- 108700028939 Amino Acyl-tRNA Synthetases Proteins 0.000 claims description 12
- MINDHVHHQZYEEK-UHFFFAOYSA-N (E)-(2S,3R,4R,5S)-5-[(2S,3S,4S,5S)-2,3-epoxy-5-hydroxy-4-methylhexyl]tetrahydro-3,4-dihydroxy-(beta)-methyl-2H-pyran-2-crotonic acid ester with 9-hydroxynonanoic acid Natural products CC(O)C(C)C1OC1CC1C(O)C(O)C(CC(C)=CC(=O)OCCCCCCCCC(O)=O)OC1 MINDHVHHQZYEEK-UHFFFAOYSA-N 0.000 claims description 10
- 229960003128 mupirocin Drugs 0.000 claims description 10
- 229930187697 mupirocin Natural products 0.000 claims description 10
- DDHVILIIHBIMQU-YJGQQKNPSA-L mupirocin calcium hydrate Chemical group O.O.[Ca+2].C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1.C[C@H](O)[C@H](C)[C@@H]1O[C@H]1C[C@@H]1[C@@H](O)[C@@H](O)[C@H](C\C(C)=C\C(=O)OCCCCCCCCC([O-])=O)OC1 DDHVILIIHBIMQU-YJGQQKNPSA-L 0.000 claims description 10
- 229940002612 prodrug Drugs 0.000 claims description 8
- 239000000651 prodrug Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 208000035143 Bacterial infection Diseases 0.000 claims description 6
- 125000000217 alkyl group Chemical group 0.000 claims description 6
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 125000004404 heteroalkyl group Chemical group 0.000 claims description 4
- 125000001072 heteroaryl group Chemical group 0.000 claims description 4
- 230000000813 microbial effect Effects 0.000 claims description 4
- 229920001515 polyalkylene glycol Polymers 0.000 claims description 4
- 241000894006 Bacteria Species 0.000 claims description 2
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims description 2
- -1 amino - Chemical class 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 208000015339 staphylococcus aureus infection Diseases 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims 8
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001408 amides Chemical class 0.000 claims 1
- 230000008029 eradication Effects 0.000 claims 1
- 210000003934 vacuole Anatomy 0.000 claims 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462073100P | 2014-10-31 | 2014-10-31 | |
| US62/073,100 | 2014-10-31 | ||
| PCT/US2015/058278 WO2016070021A1 (en) | 2014-10-31 | 2015-10-30 | Synergistic compositions for treating microbial infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538675A JP2017538675A (ja) | 2017-12-28 |
| JP2017538675A5 true JP2017538675A5 (enExample) | 2018-07-19 |
| JP6590924B2 JP6590924B2 (ja) | 2019-10-16 |
Family
ID=55858389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523903A Active JP6590924B2 (ja) | 2014-10-31 | 2015-10-30 | 微生物感染を治療するための相乗的組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US10028931B2 (enExample) |
| EP (1) | EP3212183B1 (enExample) |
| JP (1) | JP6590924B2 (enExample) |
| CN (1) | CN107106533B (enExample) |
| AU (1) | AU2015339039B2 (enExample) |
| CA (1) | CA2965839C (enExample) |
| WO (1) | WO2016070021A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108456157B (zh) * | 2017-02-22 | 2021-07-20 | 中国医学科学院药物研究所 | 1-取代苯甲酰基-4-脂酰基氨基脲类衍生物、制备方法及作为抗菌药物的用途 |
| CN110272364A (zh) * | 2018-03-13 | 2019-09-24 | 中国医学科学院药物研究所 | 1-取代苯甲酰基-4-脂酰基氨基脲类衍生物、制备方法及作为抗菌药物的用途 |
| CN116102478B (zh) * | 2021-11-09 | 2025-04-15 | 中国医学科学院药物研究所 | 1,4-二羰基氨基硫脲类化合物的制备方法和抗感染的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024407A2 (en) | 2001-09-21 | 2003-03-27 | Message Pharmaceuticals, Inc. | Inhibitors of rnase p proteins as antibacterial compounds |
| DK1879877T3 (da) | 2005-05-03 | 2013-04-15 | Ranbaxy Lab Ltd | Antimikrobielle midler |
| JP2009533315A (ja) * | 2006-04-10 | 2009-09-17 | ランバクシー ラボラトリーズ リミテッド | 抗菌剤 |
| US20110207726A1 (en) | 2008-04-17 | 2011-08-25 | The Trustees Of The University Of Pennsylvania | Inhibitors of Human Cathepsin L, Cathepsin B, and Cathepsin S |
| WO2010009368A2 (en) * | 2008-07-18 | 2010-01-21 | Oragenics, Inc. | Compositions for the detection and treatment of colorectal cancer |
| BR112013006265A2 (pt) * | 2010-09-15 | 2016-06-07 | Scripps Research Inst | espectros antibióticos gerais análogos a arilomicina |
| WO2012054738A1 (en) | 2010-10-22 | 2012-04-26 | Brown University | Combination of an aminoacyl - trna synthetase inhibitor with a further antibacterial agent for attenuating multiple drug resistance |
| EP2667872B1 (en) * | 2011-01-26 | 2019-01-02 | University Of Rochester | Small molecule rnase inhibitors and methods of use |
-
2015
- 2015-10-30 CA CA2965839A patent/CA2965839C/en active Active
- 2015-10-30 WO PCT/US2015/058278 patent/WO2016070021A1/en not_active Ceased
- 2015-10-30 EP EP15854238.1A patent/EP3212183B1/en active Active
- 2015-10-30 AU AU2015339039A patent/AU2015339039B2/en active Active
- 2015-10-30 JP JP2017523903A patent/JP6590924B2/ja active Active
- 2015-10-30 US US15/521,623 patent/US10028931B2/en active Active
- 2015-10-30 CN CN201580057031.3A patent/CN107106533B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010038081A3 (en) | 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors | |
| UA96964C2 (ru) | Соединения полициклической мочевины с антибактериальными свойствами | |
| WO2008020227A3 (en) | Antibacterial pyrrolecarboxamides | |
| WO2008020229A3 (en) | Antibacterial pyrrolecarboxamides | |
| WO2014078778A3 (en) | Antiviral azasugar-containing nucleosides | |
| WO2012065963A3 (en) | Antiviral condensed heterocyclic compounds | |
| TW200640908A (en) | Chemical compounds | |
| UA114006C2 (xx) | Похідні 5-фенокси-3h-піримідин-4-ону і їхнє застосування як інгібіторів зворотної транскриптази віл | |
| WO2008153610A3 (en) | Use of il-23 antagonists for treatment of infection | |
| WO2009123776A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| DE602004021644D1 (de) | Gyraseinhibitoren und deren verwendungen | |
| WO2009029622A3 (en) | Antiviral drugs for treatment of arenavirus infection | |
| JP2014508804A5 (enExample) | ||
| CA2862755A1 (en) | Antiviral compounds with a dibenzooxaheterocycle moiety | |
| WO2017089390A8 (en) | Janus kinases inhibitors, compositions thereof and use thereof | |
| SI2895174T1 (en) | The prodrugs of the amino quinazoline kinase inhibitor | |
| JP2017517547A5 (enExample) | ||
| JP2013542981A5 (enExample) | ||
| CN115315423A (zh) | 取代芳基类化合物 | |
| MX2011005092A (es) | Composicion de octenidina. | |
| JP2013528659A5 (enExample) | ||
| JP2017529357A5 (enExample) | ||
| JP2017519817A5 (enExample) | ||
| CN109689652A (zh) | 稠杂环类衍生物、其制备方法及其在医学上的应用 | |
| JP2014511366A5 (enExample) |